Loading
Life sciences · Journal article
Frontiers in Pharmacology · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Orlistat, a potent inhibitor of gastric and pancreatic lipases, has been a cornerstone of pharmacological obesity management for over 2 decades. By reducing dietary fat absorption, it facilitates modest but clinically significant weight loss and helps prevent weight regain when combined with lifestyle interventions. Its use is associated with improvements in a range of obesity-related comorbidities, including enhanced glycemic control, reduced risk of type 2 diabetes progression, and favorable modifications of cardiovascular risk factors such as dyslipidemia. However, its clinical utility is often limited by predictable gastrointestinal adverse effects, which can impact patient adherence. Beyond its established role in weight control, a growing body of preclinical evidence has unveiled Orlistat’s off-target activity as an inhibitor of fatty acid synthase (FASN), a key enzyme in de novo lipogenesis that is frequently overexpressed in various cancers. This discovery has spurred investigation into its potential as an anti-neoplastic agent, with studies demonstrating its ability to induce apoptosis, arrest cell cycle progression, and synergize with immunotherapy in cancer models. This review provides a comprehensive analysis of Orlistat, covering its molecular mechanisms, clinical efficacy and safety in diverse populations, impact on metabolic health, and the exciting, yet nascent, evidence for its repurposing in oncology.